Protein misfolding as an underlying molecular defect in mucopolysaccharidosis III type C
- PMID: 19823584
- PMCID: PMC2757673
- DOI: 10.1371/journal.pone.0007434
Protein misfolding as an underlying molecular defect in mucopolysaccharidosis III type C
Abstract
Mucopolysaccharidosis type IIIC or Sanfilippo syndrome type C (MPS IIIC, MIM #252930) is an autosomal recessive disorder caused by deficiency of the lysosomal membrane enzyme, heparan sulfate acetyl-CoA: alpha-glucosaminide N-acetyltransferase (HGSNAT, EC 2.3.1.78), which catalyses transmembrane acetylation of the terminal glucosamine residues of heparan sulfate prior to their hydrolysis by alpha-N-acetylglucosaminidase. Lysosomal storage of undegraded heparan sulfate in the cells of affected patients leads to neuronal death causing neurodegeneration and is accompanied by mild visceral and skeletal abnormalities, including coarse facies and joint stiffness. Surprisingly, the majority of MPS IIIC patients carrying missense mutations are as severely affected as those with splicing errors, frame shifts or nonsense mutations resulting in the complete absence of HGSNAT protein.In order to understand the effects of the missense mutations in HGSNAT on its enzymatic activity and biogenesis, we have expressed 21 mutant proteins in cultured human fibroblasts and COS-7 cells and studied their folding, targeting and activity. We found that 17 of the 21 missense mutations in HGSNAT caused misfolding of the enzyme, which is abnormally glycosylated and not targeted to the lysosome, but retained in the endoplasmic reticulum. The other 4 mutants represented rare polymorphisms which had no effect on the activity, processing and targeting of the enzyme. Treatment of patient cells with a competitive HGSNAT inhibitor, glucosamine, partially rescued several of the expressed mutants. Altogether our data provide an explanation for the severity of MPS IIIC and suggest that search for pharmaceutical chaperones can in the future result in therapeutic options for this disease.
Conflict of interest statement
Figures
Similar articles
-
Sanfilippo syndrome type C: mutation spectrum in the heparan sulfate acetyl-CoA: alpha-glucosaminide N-acetyltransferase (HGSNAT) gene.Hum Mutat. 2009 Jun;30(6):918-25. doi: 10.1002/humu.20986. Hum Mutat. 2009. PMID: 19479962 Review.
-
Analysis of the biogenesis of heparan sulfate acetyl-CoA:alpha-glucosaminide N-acetyltransferase provides insights into the mechanism underlying its complete deficiency in mucopolysaccharidosis IIIC.J Biol Chem. 2010 Oct 8;285(41):31233-42. doi: 10.1074/jbc.M110.141150. Epub 2010 Jul 22. J Biol Chem. 2010. PMID: 20650889 Free PMC article.
-
Functional analysis of the HGSNAT gene in patients with mucopolysaccharidosis IIIC (Sanfilippo C Syndrome).Hum Mutat. 2010 Jul;31(7):E1574-86. doi: 10.1002/humu.21286. Hum Mutat. 2010. PMID: 20583299
-
Glucosamine amends CNS pathology in mucopolysaccharidosis IIIC mouse expressing misfolded HGSNAT.J Exp Med. 2022 Aug 1;219(8):e20211860. doi: 10.1084/jem.20211860. Epub 2022 Jun 15. J Exp Med. 2022. PMID: 35704026 Free PMC article.
-
Glycosaminoglycans and mucopolysaccharidosis type III.Front Biosci (Landmark Ed). 2016 Jun 1;21(7):1393-409. doi: 10.2741/4463. Front Biosci (Landmark Ed). 2016. PMID: 27100513 Review.
Cited by
-
Novel therapies for mucopolysaccharidosis type III.J Inherit Metab Dis. 2021 Jan;44(1):129-147. doi: 10.1002/jimd.12316. Epub 2020 Sep 28. J Inherit Metab Dis. 2021. PMID: 32944950 Free PMC article. Review.
-
Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens.Pharmacol Res. 2014 May;83:38-51. doi: 10.1016/j.phrs.2013.12.004. Epub 2013 Dec 25. Pharmacol Res. 2014. PMID: 24373832 Free PMC article. Review.
-
Therapeutic strategies based on modified U1 snRNAs and chaperones for Sanfilippo C splicing mutations.Orphanet J Rare Dis. 2014 Dec 10;9:180. doi: 10.1186/s13023-014-0180-y. Orphanet J Rare Dis. 2014. PMID: 25491247 Free PMC article.
-
High-Throughput Screen Fails to Identify Compounds That Enhance Residual Enzyme Activity of Mutant N-Acetyl-α-Glucosaminidase in Mucopolysaccharidosis Type IIIB.JIMD Rep. 2018;39:97-106. doi: 10.1007/8904_2017_51. Epub 2017 Aug 24. JIMD Rep. 2018. PMID: 28836185 Free PMC article.
-
Structure of the human heparan-α-glucosaminide N-acetyltransferase (HGSNAT).Elife. 2024 Aug 28;13:RP93510. doi: 10.7554/eLife.93510. Elife. 2024. PMID: 39196614 Free PMC article.
References
-
- Neufeld EF, Muenzer J. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill; 2001. The mucopolysaccharidoses in Scriver CR, Beaudet AL, Sly WS, Valle D, Editors. pp. 3421–3452.
-
- Bartsocas C, Grobe H, van de Kamp JJP, von Figura K, Kresse H, et al. Sanfilippo type C disease: clinical findings in four patients with a new variant of mucopolysaccharidosis III. Eur J Pediatr. 1979;130:251–258. - PubMed
-
- Valstar MJ, Ruijter, GJG, van Diggelen OP, Poorthuis BJ, Wijburg FA. Sanfilippo syndrome: A mini-review. J Inherit Metab Dis. 2008;31:240–252. - PubMed
-
- Berger-Plantinga EG, Vanneste JA, Groener JE, van Schooneveld MJ. Adult-onset dementia and retinitis pigmentosa due to mucopolysaccharidosis III-C in two sisters. J Neurol. 2004;251:479–481. - PubMed
-
- Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249–254. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
